Growth pattern in children with X-linked hypophosphatemia treated with burosumab and growth hormone.

Diana-Alexandra ErtlJustin Le LorierAndreas GleissSéverine TrabadoCandace BensignorChristelle AudrainVolha ZhukouskayaRégis CoutantJugurtha BerkenouAnya RothenbuhlerGabriele HaeuslerAgnès Linglart

Published in: Orphanet journal of rare diseases (2022)

To our knowledge, this is the first study on growth under concomitant rhGH and burosumab treatments. We did not observe any safety issue in this cohort of patients which is one of the largest in Europe. Our data suggest that continuing treatment with rhGH after switching from conventional therapy to burosumab, if the height prognosis is compromised, might be beneficial for the final height.

Keyphrases

growth hormone
body mass index
newly diagnosed
end stage renal disease
ejection fraction
prognostic factors
stem cells
big data
patient reported outcomes
replacement therapy
combination therapy
smoking cessation